Axonics, Inc. (AXNX) Tops Q1 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Axonics® Reports First Quarter 2022 Financial Results
May 5, 2022 4:01 PM EDTIRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2022.
We are pleased with this quarters revenue result considering the significant impact the Omicron surge had on elective procedures in January and February, said Raymond W. Cohen, chief executive officer of Axonics. Sacral neuromodulation procedure volumes recovered nicely in March and continued to trend favorably in April. Bulkamid® generated yet another quarter of... More
